November Nearly Doubled This Biotech's Shares

November saw Celsion (NASDAQ: CLSN  )  shares climb 71%, putting the stock at a year-to-date total of a 360% gain. The company is advancing its ThermoDox process through phase 3 trials for liver cancer. The process uses heat-sensitive nanoparticles that are then heated through RF ablation to kill tumors. More focus will be on this company in the near future as it moves closer to its phase 3 results, but as with any biotech stock with an upcoming binary event that could really drive share prices either way, the risk is inherently high; if the tests are a failure, the sell-off could be enormous.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2142878, ~/Articles/ArticleHandler.aspx, 4/19/2014 6:38:14 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement